

Resource Summary Report

Generated by [dkNET](#) on Jul 31, 2026

Multi-rAb Polymer HRP-Goat Anti-Rabbit Recombinant Secondary Antibody (H+L)

RRID:AB_3094534

Type: Antibody

Proper Citation

Proteintech Cat# RGAR011, RRID:AB_3094534

Antibody Information

URL: http://antibodyregistry.org/AB_3094534

Proper Citation: Proteintech Cat# RGAR011, RRID:AB_3094534

Target Antigen: IgG heavy and light chain

Host Organism: Goat

Clonality: recombinant monoclonal secondary

Comments: Applications: IHC

Antibody Name: Multi-rAb Polymer HRP-Goat Anti-Rabbit Recombinant Secondary Antibody (H+L)

Description: This recombinant monoclonal secondary targets IgG heavy and light chain

Target Organism: rabbit

Antibody ID: AB_3094534

Vendor: Proteintech

Catalog Number: RGAR011

Record Creation Time: 20250820T001942+0000

Record Last Update: 20250820T075858+0000

Ratings and Alerts

No rating or validation information has been found for Multi-rAb Polymer HRP-Goat Anti-Rabbit Recombinant Secondary Antibody (H+L).

No alerts have been found for Multi-rAb Polymer HRP-Goat Anti-Rabbit Recombinant Secondary Antibody (H+L).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Cao K, et al. (2025) RFX2-BNIP3 axis-driven adaptive mitophagy promotes resistance to ACK1-targeted therapy in non-small cell lung cancer. *Oncogene*, 44(37), 3461.

Ke B, et al. (2025) LINC00323 knockdown suppresses the proliferation, migration, and vascular mimicry of non-small cell lung cancer cells by promoting ubiquitinated degradation of AKAP1. *Non-coding RNA research*, 11, 131.

Patil NY, et al. (2025) Cinnabarinic acid protects against metabolic dysfunction-associated steatohepatitis by activating aryl hydrocarbon receptor-dependent AMPK signaling. *American journal of physiology. Gastrointestinal and liver physiology*, 328(4), G433.

Cao K, et al. (2025) Integrating bulk, single-cell, and spatial transcriptomics to identify and functionally validate novel targets to enhance immunotherapy in NSCLC. *NPJ precision oncology*, 9(1), 112.